EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Within-host co-evolution of KPC variants: plasmid-mediated dissemination of bla Kpc-194 and bla Kpc-33 in ST11-KL64 hypervirulent Klebsiella pneumoniae driving ceftazidime-avibactam resistance

Li Ding iD, Xiangbing Wu, Qiang Xie, Liting Liu, Bingshao Liang iD, Siquan Shen, Yan Guo, Jing Chen, Fupin Hu iD

Microbiology Spectrum · 07.04.2026 · 14 (4)

DOI: 10.1128/spectrum.03257-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Microbiology Spectrum, erschienen am 07.04.2026. Verfasst von Li Ding und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Ceftazidime, Klebsiella pneumoniae, Azabicyclo Compounds, Anti-Bacterial Agents. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, China Antimicrobial Surveillance Network.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

KPC variants are the primary cause of treatment failure in patients with Klebsiella pneumoniae infections. This study reports the molecular mechanism by which two novel KPC variants (KPC-194 and KPC-33), isolated from a single patient, mediate resistance to ceftazidime-avibactam in ST11-KL64 K. pneumoniae , as well as the evolutionary trajectory of these variants within the host. The broth microdilution method (BMD) was used to determine bacterial susceptibility to antimicrobial agents. Whole-genome sequencing (WGS) technology was employed to identify the drug-resistant genes, virulence genes, and genetic environment carried by the bacterial strains. Molecular cloning experiments and plasmid conjugation experiments were conducted to clarify the susceptibility of KPC-194 to ceftazidime-avibactam and carbapenem. The BMD showed that the KPC-194-producing K. pneumoniae strain was resistant to ceftazidime-avibactam and other antimicrobial agents but susceptible to imipenem (with a minimum inhibitory concentration [MIC] of 0.5 mg/L). Compared with KPC-2, KPC-194 had two amino acid changes, namely, D179Y and P183L. In comparison with Escherichia coli EC 600, the MIC of ceftazidime-avibactam against E. coli EC 600 carrying the bla KPC-194 plasmid increased by 256-fold. When compared with pHSG398-DH5α, the MIC of ceftazidime-avibactam against the cloned strain bla KPC-194 -pHSG398-DH5α was elevated by 64-fold. WGS revealed that bla KPC-194 was located on both the IncFII(pHN7A8)-type plasmid and the IncR-type plasmid and that it was horizontally transferred from the IncR-type plasmid to the IncFII(pHN7A8)-type plasmid via an IS 26 -mediated replicative transposition mechanism. This study elucidates the key mechanism by which the novel KPC variant, KPC-194 (D179Y/P183L), mediates resistance to ceftazidime-avibactam. IMPORTANCE This study elucidates the critical molecular mechanism and evolutionary pathway of a novel KPC variant, KPC-194, that confers resistance to the last-resort antibiotic combination ceftazidime-avibactam in a high-risk Klebsiella pneumoniae strain. We identified that two amino acid substitutions (D179Y/P183L) in KPC-194 are responsible for ceftazidime-avibactam resistance. Crucially, our work reveals a dual-threat dynamic: the resistance phenotype is not only caused by the KPC mutation but also profoundly exacerbated by horizontal gene transfer. bla KPC-194 mobilized from a low-risk IncR plasmid to a highly transmissible IncFII plasmid via IS26-mediated replicative transposition. This event dramatically enhances the potential for widespread dissemination among clinical pathogens.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CeftazidimeKlebsiella pneumoniaeAzabicyclo CompoundsAnti-Bacterial AgentsKlebsiella Infectionsbeta-LactamasesDrug Resistance, Multiple, BacterialBacterial ProteinsPlasmidsDrug CombinationsHumansMicrobial Sensitivity TestsThird Generation CephalosporinsEvolution, MolecularWhole Genome Sequencing

Stichwörter der Autor:innen

K. pneumoniaeKPC variantsKPC-194KPC-2ceftazidime-avibactam

Substanzen

CeftazidimeAzabicyclo Compoundsavibactam, ceftazidime drug combinationAnti-Bacterial Agentsbeta-LactamasesDrug CombinationsBacterial ProteinsThird Generation Cephalosporins

Autor:innen und Institutionen

  • Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China.
  • Key Laboratory of Clinical Pharmacology of Antibiotics, Ministry of Health, Shanghai, China.
  • Department of Laboratory Medicine, Wenzhou Central Hospital, Wenzhou, Zhejiang, China.
  • Department of Laboratory Medicine, The Affiliated Chuzhou Hospital of Anhui Medical University (The First People's Hospital of Chuzhou), Chuzhou, Anhui, China.
  • Zhongshan Hospital of Traditional Chinese Medicine, Zhongshan, Guangdong, China.
  • Clinical Laboratory, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, China.

ORCID-Profile: Li Ding, Bingshao Liang, Fupin Hu

Förderung

  • National Natural Science Foundation of China
  • China Antimicrobial Surveillance Network

Zitieren

APA

Ding, L., Wu, X., Xie, Q., Liu, L., Liang, B., Shen, S., Guo, Y., Chen, J., & Hu, F. (2026). Within-host co-evolution of KPC variants: plasmid-mediated dissemination of bla Kpc-194 and bla Kpc-33 in ST11-KL64 hypervirulent Klebsiella pneumoniae driving ceftazidime-avibactam resistance. Microbiology Spectrum, 14(4). https://doi.org/10.1128/spectrum.03257-25

Vancouver

Ding L, Wu X, Xie Q, Liu L, Liang B, Shen S, et al. Within-host co-evolution of KPC variants: plasmid-mediated dissemination of bla Kpc-194 and bla Kpc-33 in ST11-KL64 hypervirulent Klebsiella pneumoniae driving ceftazidime-avibactam resistance. Microbiology Spectrum. 2026;14(4). doi:10.1128/spectrum.03257-25

BibTeX
@article{Ding2026,
  author = {Ding, Li and Wu, Xiangbing and Xie, Qiang and Liu, Liting and Liang, Bingshao and Shen, Siquan and Guo, Yan and Chen, Jing and Hu, Fupin},
  title = {Within-host co-evolution of KPC variants: plasmid-mediated dissemination of bla Kpc-194 and bla Kpc-33 in ST11-KL64 hypervirulent Klebsiella pneumoniae driving ceftazidime-avibactam resistance},
  journal = {Microbiology Spectrum},
  year = {2026},
  volume = {14},
  number = {4},
  doi = {10.1128/spectrum.03257-25}
}
Kostenlos starten →